13F Holdings
中文EN

EVFM Evofem Biosciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1618835 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.0%
TTM net income YoY-133.9%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR9.3%
Net income 3-yr CAGR—

Margins

Gross margin75.9%
Operating margin-16.8%
Net margin-71.7%
FCF margin—
EBITDA margin-16.7%

Returns

ROE—
ROA-120.6%
ROIC (approx.)—
Asset turnover1.68x

Leverage & solvency

Liabilities / assets1,184.7%
Debt / equity—
Current ratio0.07x
Interest coverage-1.18x

Cash quality & payout

Operating cash flow / net income0.05x
Accruals ratio-115.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$20.18M$19.36M$18.22M$16.84M$8.24M
Cost of revenue$4.62M$3.83M$6.51M$4.42M$4.05M
Gross profit$15.57M$15.53M$11.71M$12.42M$4.19M
R&D expense—$1.84M$2.94M$25.03M$33.13M
SG&A expense$7.39M$11.56M$14.95M$27.56M$24.71M
Operating income$3.37M-$7.68M-$17.85M-$84.12M-$166.80M
Interest expense$2.37M$2.24M$2.27M$2.18M$2.67M
Pretax income$393,000-$8.86M$53.00M-$76.65M-$205.18M
Income tax$2,000—$17,000$44,000$17,000
Net income$391,000-$8.86M$52.98M-$76.70M-$205.19M
EBITDA$3.39M-$7.65M-$17.37M-$83.11M-$165.78M
EPS (basic)0.00-0.1110.36-167.42-23.63
EPS (diluted)0.00-0.110.05-167.42-23.63
Weighted avg. shares (diluted)6.42B80.00M984.04M465,9678.73M
Balance sheet
Cash & equivalents$578,000$741,000$580,000$4.78M$13.59M
Receivables$12.48M$9.83M$5.74M$1.13M$6.45M
Inventory$1.13M$1.58M$1.70M$5.38M$7.67M
Current assets$15.28M$13.61M$9.21M$12.70M$30.14M
PP&E, net$418,000$458,000$1.20M$3.94M$5.77M
Intangibles$4.35M$9.60M———
Total assets$20.27M$23.79M$10.55M$25.16M$42.51M
Current liabilities$84.82M$80.45M$72.46M$93.83M$137.66M
Short-term debt$147,000$135,000———
Total liabilities$89.71M$90.26M$72.47M$96.96M$142.09M
Shareholders' equity-$74.34M-$71.26M-$66.51M-$71.80M-$104.31M
Shares outstanding126.69M113.36M20.01M984,78610.83M
Cash flow statement
Operating cash flow-$1.99M-$3.88M-$8.97M-$70.41M-$146.67M
Capital expenditure$5,000$14,000$4,000$341,000$2.94M
Free cash flow-$2.00M-$3.90M-$8.97M-$70.75M-$149.61M
Investing cash flow-$62,000-$569,000-$4,000-$341,000-$2.69M
Financing cash flow$1.89M$4.62M$4.78M$61.94M$90.69M
Depreciation & amortization$19,000$30,000$477,000$1.01M$1.02M
Stock-based compensation$166,000$847,000$1.19M$3.31M$8.90M
Share buybacks———$18,000$0

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.